• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

感染:发病机制与疫苗研发

Infections: Pathogenesis and Vaccine Development.

作者信息

Jiang Zhulin, Li Shuihong, Zhu Cuiming, Zhou Runjie, Leung Polly H M

机构信息

Institution of Pathogenic Biology, Hengyang Medical College, University of South China, Hengyang 421001, China.

Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong 999077, China.

出版信息

Pathogens. 2021 Jan 25;10(2):119. doi: 10.3390/pathogens10020119.

DOI:10.3390/pathogens10020119
PMID:33503845
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7911756/
Abstract

is a major causative agent of community-acquired pneumonia which can lead to both acute upper and lower respiratory tract inflammation, and extrapulmonary syndromes. Refractory pneumonia caused by can be life-threatening, especially in infants and the elderly. Here, based on a comprehensive review of the scientific literature related to the respective area, we summarize the virulence factors of and the major pathogenic mechanisms mediated by the pathogen: adhesion to host cells, direct cytotoxicity against host cells, inflammatory response-induced immune injury, and immune evasion. The increasing rate of macrolide-resistant strains and the harmful side effects of other sensitive antibiotics (e.g., respiratory quinolones and tetracyclines) in young children make it difficult to treat, and increase the health risk or re-infections. Hence, there is an urgent need for development of an effective vaccine to prevent infections in children. Various types of vaccines have been reported, including whole-cell vaccines (inactivated and live-attenuated vaccines), subunit vaccines (involving protein P1, protein P30, protein P116 and CARDS toxin) and DNA vaccines. This narrative review summarizes the key pathogenic mechanisms underlying infection and highlights the relevant vaccines that have been developed and their reported effectiveness.

摘要

是社区获得性肺炎的主要病原体,可导致急性上呼吸道和下呼吸道炎症以及肺外综合征。由其引起的难治性肺炎可能危及生命,尤其是在婴儿和老年人中。在此,基于对相关领域科学文献的全面综述,我们总结了该病原体的毒力因子以及由该病原体介导的主要致病机制:与宿主细胞的粘附、对宿主细胞的直接细胞毒性、炎症反应诱导的免疫损伤和免疫逃逸。大环内酯类耐药菌株的增加率以及其他敏感抗生素(如呼吸喹诺酮类和四环素类)对幼儿的有害副作用使得治疗变得困难,并增加了健康风险或再次感染的风险。因此,迫切需要开发一种有效的疫苗来预防儿童感染。已经报道了各种类型的该病原体疫苗,包括全细胞疫苗(灭活疫苗和减毒活疫苗)、亚单位疫苗(涉及该病原体蛋白P1、蛋白P30、蛋白P116和CARDS毒素)和DNA疫苗。本叙述性综述总结了该病原体感染的关键致病机制,并强调了已开发的相关疫苗及其报道的有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cfe/7911756/a90cf315fd5d/pathogens-10-00119-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cfe/7911756/f3806a208e9b/pathogens-10-00119-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cfe/7911756/a90cf315fd5d/pathogens-10-00119-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cfe/7911756/f3806a208e9b/pathogens-10-00119-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cfe/7911756/a90cf315fd5d/pathogens-10-00119-g002.jpg

相似文献

1
Infections: Pathogenesis and Vaccine Development.感染:发病机制与疫苗研发
Pathogens. 2021 Jan 25;10(2):119. doi: 10.3390/pathogens10020119.
2
An attenuated multiple genetic mutant of Mycoplasma pneumoniae imparts good immuno-protection against M. pneumoniae pneumonia in BALB/c mice.肺炎支原体的一种减毒多重基因突变体对BALB/c小鼠的肺炎支原体肺炎具有良好的免疫保护作用。
Microb Pathog. 2022 Apr;165:105463. doi: 10.1016/j.micpath.2022.105463. Epub 2022 Mar 1.
3
Pathogenesis of Mycoplasma pneumoniae: An update.肺炎支原体的发病机制:最新进展
Indian J Med Microbiol. 2016 Jan-Mar;34(1):7-16. doi: 10.4103/0255-0857.174112.
4
Impact of viral coinfection and macrolide-resistant mycoplasma infection in children with refractory Mycoplasma pneumoniae pneumonia.病毒混合感染和大环内酯类耐药支原体感染对难治性肺炎支原体肺炎患儿的影响。
BMC Infect Dis. 2020 Aug 26;20(1):633. doi: 10.1186/s12879-020-05356-1.
5
Insight into the Pathogenic Mechanism of Mycoplasma pneumoniae.探讨肺炎支原体的致病机制。
Curr Microbiol. 2022 Dec 2;80(1):14. doi: 10.1007/s00284-022-03103-0.
6
Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance.肺炎支原体肺炎抗菌治疗选择概述:关注大环内酯类耐药性
Clin Respir J. 2017 Jul;11(4):419-429. doi: 10.1111/crj.12379. Epub 2015 Oct 13.
7
Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children.用于儿童支原体肺炎继发社区获得性下呼吸道感染的抗生素。
Cochrane Database Syst Rev. 2010 Jul 7(7):CD004875. doi: 10.1002/14651858.CD004875.pub3.
8
Antibiotics for community-acquired lower respiratory tract infections secondary to Mycoplasma pneumoniae in children.用于儿童支原体肺炎继发社区获得性下呼吸道感染的抗生素。
Cochrane Database Syst Rev. 2012 Sep 12(9):CD004875. doi: 10.1002/14651858.CD004875.pub4.
9
Mycoplasma pneumoniae infections--does treatment help?肺炎支原体感染——治疗有帮助吗?
J Infect. 2014 Nov;69 Suppl 1:S42-6. doi: 10.1016/j.jinf.2014.07.017. Epub 2014 Sep 26.
10
Exploring the pathogenetic mechanisms of (Review).探索(疾病)的发病机制(综述) 。 (注:原文括号处内容缺失,翻译时根据语境补充了“疾病”一词使译文更通顺)
Exp Ther Med. 2024 Apr 30;28(1):271. doi: 10.3892/etm.2024.12559. eCollection 2024 Jul.

引用本文的文献

1
Editorial: Current molecular, immunological, pathological and clinical aspects of pathogenic infections.社论:致病性感染的当前分子、免疫、病理及临床方面
Front Cell Infect Microbiol. 2025 Aug 8;15:1665283. doi: 10.3389/fcimb.2025.1665283. eCollection 2025.
2
Changes in epidemiological and clinical features in children before, during, and after the COVID-19 pandemic in Shanghai, China.中国上海新冠疫情期间及前后儿童的流行病学和临床特征变化
Microbiol Spectr. 2025 Sep 2;13(9):e0288824. doi: 10.1128/spectrum.02888-24. Epub 2025 Aug 7.
3
Advances in adhesion-related pathogenesis in infection.

本文引用的文献

1
Concomitant infection with COVID-19 and Mycoplasma pneumoniae.同时感染新型冠状病毒和肺炎支原体。
Biomed J. 2020 Oct;43(5):458-461. doi: 10.1016/j.bj.2020.07.002. Epub 2020 Jul 14.
2
Association of mortality and recent Mycoplasma pneumoniae infection in COVID-19 patients.新冠肺炎患者的死亡率与近期肺炎支原体感染的关系。
J Med Virol. 2021 Feb;93(2):1180-1183. doi: 10.1002/jmv.26467. Epub 2020 Sep 29.
3
Clinical features and outcomes of adult COVID-19 patients co-infected with Mycoplasma pneumoniae.成人新冠病毒病患者合并肺炎支原体感染的临床特征及转归
感染中黏附相关发病机制的进展。
Front Microbiol. 2025 Jul 23;16:1613760. doi: 10.3389/fmicb.2025.1613760. eCollection 2025.
4
Role of Inflammatory Markers as a Risk Factor for Community-Acquired Pneumonia Management.炎症标志物作为社区获得性肺炎管理危险因素的作用。
Medicina (Kaunas). 2025 Jun 11;61(6):1078. doi: 10.3390/medicina61061078.
5
CCL20 Expression via AKT-ERK1/2-AP1 Pathway in Infection: Implications for EMT and Cell Migration.CCL20通过AKT-ERK1/2-AP1途径在感染中的表达:对上皮-间质转化和细胞迁移的影响
J Inflamm Res. 2025 Apr 28;18:5727-5739. doi: 10.2147/JIR.S512408. eCollection 2025.
6
Understanding the unconventional reemergence of epidemics during the COVID-19 pandemic.理解新冠疫情期间传染病的非常规再次出现。
Transl Pediatr. 2025 Mar 31;14(3):473-479. doi: 10.21037/tp-24-482. Epub 2025 Mar 26.
7
Rapid detection of CARDS toxin in clinical respiratory specimens by a loop-mediated isothermal amplification assay.通过环介导等温扩增法快速检测临床呼吸道标本中的CARDS毒素。
Front Cell Infect Microbiol. 2025 Mar 5;15:1496829. doi: 10.3389/fcimb.2025.1496829. eCollection 2025.
8
Atypical pathogen community-acquired pneumonia: an analysis of clinical characteristics, drug treatment, and prognosis in the related patients.非典型病原体社区获得性肺炎:相关患者的临床特征、药物治疗及预后分析
Mol Biol Rep. 2025 Mar 14;52(1):309. doi: 10.1007/s11033-025-10382-w.
9
Predictive Significance of Admission-Day Blood Routine-Derived Indices for 30-Day Mortality Risk in Elderly Patients with Bacterial Pneumonia.入院当日血常规衍生指标对老年细菌性肺炎患者30天死亡风险的预测意义
Int J Gen Med. 2025 Mar 5;18:1295-1309. doi: 10.2147/IJGM.S501744. eCollection 2025.
10
Mycoplasma pneumoniae-Induced Erythema Multiforme in an 11-Year-Old Boy: Diagnostic and Therapeutic Challenges.一名11岁男孩的肺炎支原体诱发多形红斑:诊断与治疗挑战
Cureus. 2025 Mar 3;17(3):e79944. doi: 10.7759/cureus.79944. eCollection 2025 Mar.
J Infect. 2020 Sep;81(3):e12-e15. doi: 10.1016/j.jinf.2020.07.010. Epub 2020 Jul 8.
4
Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia.儿童社区获得性肺炎中耐大环内酯类肺炎支原体感染。
Emerg Infect Dis. 2020 Jul;26(7):1382-1391. doi: 10.3201/eid2607.200017.
5
Vaccination using inactivated Mycoplasma pneumoniae induces detrimental infiltration of neutrophils after subsequent infection in mice.使用灭活的肺炎支原体进行疫苗接种会导致小鼠随后感染后中性粒细胞的有害浸润。
Vaccine. 2020 Jul 6;38(32):4979-4987. doi: 10.1016/j.vaccine.2020.05.074. Epub 2020 Jun 11.
6
Presenting characteristics, comorbidities, and outcomes of patients coinfected with COVID-19 and Mycoplasma pneumoniae in the USA.分析美国 COVID-19 合并肺炎支原体感染患者的特征、合并症和结局。
J Med Virol. 2020 Oct;92(10):2181-2187. doi: 10.1002/jmv.26026. Epub 2020 May 25.
7
Coinfection and Other Clinical Characteristics of COVID-19 in Children.儿童 COVID-19 的合并感染和其他临床特征。
Pediatrics. 2020 Jul;146(1). doi: 10.1542/peds.2020-0961. Epub 2020 May 6.
8
Characterization of an Immunoglobulin Binding Protein (IbpM) From .来自……的一种免疫球蛋白结合蛋白(IbpM)的特性分析
Front Microbiol. 2020 Apr 16;11:685. doi: 10.3389/fmicb.2020.00685. eCollection 2020.
9
Rates of Co-infection Between SARS-CoV-2 and Other Respiratory Pathogens.SARS-CoV-2 与其他呼吸道病原体的合并感染率。
JAMA. 2020 May 26;323(20):2085-2086. doi: 10.1001/jama.2020.6266.
10
Cell surface processing of the P1 adhesin of Mycoplasma pneumoniae identifies novel domains that bind host molecules.肺炎支原体 P1 黏附素的细胞表面加工鉴定出与宿主分子结合的新结构域。
Sci Rep. 2020 Apr 14;10(1):6384. doi: 10.1038/s41598-020-63136-y.